We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-0.77%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$3.11B
AUM Growth
-$180M
Cap. Flow
-$9.91M
Cap. Flow %
-0.32%
Top 10 Hldgs %
73.57%
Holding
71
New
5
Increased
9
Reduced
9
Closed
13
Avg Time Held
5.7 quarters
Top 10 Avg Time Held
7.9 quarters
Top 20 Avg Time Held
6.5 quarters

Top Buys

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$40.2M
2
RVMD icon
Revolution Medicines
RVMD
+$22M
3
ZYME icon
Zymeworks
ZYME
+$22M
4
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$21.1M
5
ARVN icon
Arvinas
ARVN
+$18.8M

Top Sells

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$66.2M
2
VTYX icon
Ventyx Biosciences
VTYX
+$13.1M
3
TSVT icon
2seventy bio
TSVT
+$10.7M
4
GERN icon
Geron
GERN
+$9.75M
5
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$9.72M

Sector Composition

Rank Sector Weight
1 Healthcare 99.82%
2 Miscellaneous 0.11%
3 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PRTA icon
1
Prothena Corp
PRTA
$433M
$561M 18.08%
11,584,280
– –
2018 Q4
17 quarters
SRPT icon
2
Sarepta Therapeutics
SRPT
$1.76B
$413M 13.31%
2,999,453
– –
2022 Q1
4 quarters
APLS icon
3
DELISTED
Apellis Pharmaceuticals
APLS
$360M 11.58%
5,451,647
+268,216
+5% +$15.5M
2021 Q4
5 quarters
LKFT icon
4
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.91B
$164M 5.28%
4,244,645
+513,915
+14% +$21.1M
2021 Q3
6 quarters
ANAB icon
5
AnaptysBio
ANAB
$1.39B
$164M 5.27%
7,521,024
– –
2019 Q4
13 quarters
XNCR icon
6
Xencor
XNCR
$1.76B
$147M 4.74%
5,282,516
– –
2018 Q4
17 quarters
MORF icon
7
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$145M 4.66%
3,846,966
-104,600
-3% -$3.85M
2019 Q2
15 quarters
RVMD icon
8
Revolution Medicines
RVMD
$41.8B
$116M 3.73%
5,352,183
+893,452
+20% +$22M
2022 Q1
4 quarters
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$3.27B
$113M 3.63%
5,991,479
– –
2021 Q4
5 quarters
ARVN icon
10
Arvinas
ARVN
$444M
$102M 3.27%
3,717,788
+594,488
+19% +$18.8M
2021 Q4
5 quarters
ZYME icon
11
Zymeworks
ZYME
$1.78B
$91.2M 2.94%
10,087,473
+2,518,900
+33% +$22M
2022 Q4
1 quarter
SWTX icon
12
DELISTED
SpringWorks Therapeutics
SWTX
$89.1M 2.87%
3,460,208
– –
2022 Q3
2 quarters
KURA icon
13
Kura Oncology
KURA
$859M
$81.2M 2.61%
6,638,371
– –
2015 Q4
29 quarters
RLAY icon
14
Relay Therapeutics
RLAY
$3.72B
$68.6M 2.21%
4,163,824
– –
2020 Q3
10 quarters
JANX icon
15
Janux Therapeutics
JANX
$1.04B
$46.4M 1.5%
3,838,486
+2,417,167
+170% +$40.2M
2021 Q2
7 quarters
VYGR icon
16
Voyager Therapeutics
VYGR
$129M
$29.7M 0.96%
3,851,507
-902,400
-19% -$7.18M
2021 Q3
6 quarters
DYN icon
17
Dyne Therapeutics
DYN
$2.77B
$26.8M 0.86%
2,322,384
– –
2022 Q4
1 quarter
NGM
18
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$26.3M 0.85%
6,435,518
– –
2022 Q1
4 quarters
ALEC icon
19
Alector
ALEC
$208M
$25.1M 0.81%
4,056,548
– –
2021 Q1
8 quarters
KYMR icon
20
Kymera Therapeutics
KYMR
$8.88B
$23.6M 0.76%
796,093
– –
2022 Q3
2 quarters
EWTX icon
21
Edgewise Therapeutics
EWTX
$4.05B
$23.3M 0.75%
3,493,194
– –
2021 Q1
8 quarters
NUVB icon
22
Nuvation Bio
NUVB
$1.67B
$23.1M 0.74%
13,896,543
– –
2021 Q1
8 quarters
ALLO icon
23
Allogene Therapeutics
ALLO
$432M
$22.2M 0.71%
4,488,200
– –
2022 Q2
3 quarters
CNTA
24
DELISTED
Centessa Pharmaceuticals
CNTA
$21.6M 0.7%
5,618,779
+386,500
+7% +$1.41M
2021 Q2
7 quarters
CRNX icon
25
DELISTED
Crinetics Pharmaceuticals
CRNX
$21.4M 0.69%
1,330,263
– –
2021 Q4
5 quarters
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2023 Portfolio in Review

As of Q1 2023, EcoR1 Capital held 71 positions worth $3.11B, down 5.5% from $3.29B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

EcoR1 Capital's Q1 2023 filing shows 5 new, 9 increased, 9 reduced and 13 closed positions. Its largest new stake was Generation Bio: 195,658 shares worth $8.41M. The largest sale was Zai Lab, an estimated $66.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous and Financials.

  • EcoR1 Capital's largest Q1 2023 buy was Generation Bio: 195,658 shares worth $8.41M.
  • EcoR1 Capital added most to Janux Therapeutics in Q1 2023, an estimated $40.2M increase.
  • EcoR1 Capital's biggest Q1 2023 reduction was Cullinan Oncology, cutting an estimated $8.69M.
  • EcoR1 Capital fully exited Zai Lab in Q1 2023, selling an estimated $66.2M.
  • EcoR1 Capital's ten largest holdings make up 74% of its $3.11B portfolio in Q1 2023.
  • EcoR1 Capital opened 5 new positions and closed 13 in Q1 2023.
  • EcoR1 Capital's portfolio value fell 5.5% quarter-over-quarter to $3.11B.

Based on EcoR1 Capital's 13F filing for Q1 2023, filed 15 May 2023.